Germany cancer biomarker market is anticipated to grow at a CAGR of 11.8% during the forecast period. Germany has well developed healthcare system and favorable government policies which are driving the global cancer biomarker market in the region. Adoption of specialized procedures to treat cancer, extensive R&D in the cancer treatments and presence of globally renowned major hospitals, research centers and clinics are contributing to the growth of the market. The healthcare expenditure of Germany in 2013 was 11.6% as compared to the OECD average of 8.9%. The healthcare of Germany is driven by the specific mechanisms that determine the utilization of health care in the elderly. In Germany health insurance is mandatory for the entire population Regardless of the type of health insurance, all beneficiaries have has accessed by outpatient physician and non-physician services, hospital care, rehabilitation, dental care, prescription drugs, medical supplies and long-term nursing care.

Request a Free Sample of our Germany Cancer Biomarker Market: https://www.omrglobal.com/request-sample/germany-cancer-biomarker-market

Germany has well-developed healthcare infrastructure. A number of organizations has been established in the country regarding research activities, which significantly contributes to the Germany cancer biomarker market. German Cancer Aid was established in 1974, in order to promote research, improve care for cancer patients and increase cancer awareness through information, education and public campaigns. Krebsallianz GmbH is a medical relief program focused on cancer and is funding childhood cancer research in Germany. German Children's Cancer Foundation is established to provide support, social fund, aftercare, pirate forest camp, cancer information and supporting research in 1995.

A full Report of Germany Cancer Biomarker Market is Available at: https://www.omrglobal.com/industry-reports/germany-cancer-biomarker-market

Apart from cancer organization, a number of cancers centers has been established. Cancer centers can be defined as hospitals and research institutes cater to a designated region. Some of the major cancer center are Centre for Integrated Oncology (CIO), Charité Comprehensive Cancer Centre, Comprehensive Cancer Centre Erlangen EMN, National Centre for Tumor Diseases (NCT) Heidelberg, Tumor Centre Freiburg, University Centre for Tumor Diseases Frankfurt (UCT), University Cancer Centre Hamburg, West German Tumor Centre. Thus, this is expected to influence the growth of the Germany cancer biomarker market during the forecast period.

Germany Cancer Biomarker Market Segmentation

By Biomarker Type

• Genetic Biomarker
• Protein Biomarker

By Cancer Type

• Lung Cancer
• Prostate Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Other

By Applications
• Drug Discovery and Development
• Diagnosis
• Risk Assessment
• Prognostics
By Profiling Technology
• Omics Technology
• Immunoassays
• Cytogenetics
• Bioinformatics
Company Profiles
• Abbott Laboratories Inc.
• Astellas Pharma Inc.
• Becton, Dickson and Co.
• Bio-Rad Laboratories, Inc.
• Danaher Corp.
• F. Hoffmann-La Roche Ltd.
• Merck and Co., Inc.
• Novartis AG
• Pfizer Inc.
• QIAGEN GmbH
• Thermo Fisher Scientific Inc.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/germany-cancer-biomarker-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404